Ratio between biological and targeted synthetic disease-modifying anti-rheumatic drugs and glucocorticoid use in various countries: results from METEOR
Authors' conclusion
In this analysis based on eight different countries, we show that the btsDMARD/GC ratio varies widely across countries. This was strongly associated with general country-level indicators of level of wealth, i.e. greater wealth was associated with a higher ratio.
Study context
- Population
- Patients with rheumatoid arthritis (RA) in eight geographically spread countries, METEOR registry, 1 January 2007 to 13 September 20218,484 from India
- Participants
- 10,856 patients
- Outcome
- Ratio of proportion ever using a btsDMARD to proportion ever using a GC and never a btsDMARD, per country, and its association with country-level SES
- Follow-up
- 2 years
Methodological detailsinternational observational registry (METEOR), linear regression
- International observational registry (METEOR)
- Linear regression
Main finding
As reported in the abstract
Estimated increase in btsDMARD/glucocorticoid (GC) ratio per additional 10 000 International $ GDP per capita
0.1
95% CI 0.05;0.1
Estimated increase in btsDMARD/GC ratio per additional 10 000 International $ household net adjusted disposable income
0.2
95% CI 0.08;0.3
Estimated increase in btsDMARD/GC ratio per additional 10 000 International $ health expenditure per capita
0.6
95% CI 0.4;0.8
Observational data: associations, not effects.
Further findings
Drug use by country · 2 years of follow-up
- btsDMARD (with or without GC) use, from South Africa, India to Massachusetts, USA
- 1% to 26%
- GC and never btsDMARD use, from UK to South Africa
- 19% to 92%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →